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ABSTRACT
Objective: To estimate the prevalence and incidence
of type 2 diabetes using a national pharmacy claims
database.
Research design and methods: We used data from
the Health Service Executive-Primary Care
Reimbursement Service database in Ireland for this
cross-sectional study. Prevalent cases of type 2
diabetes were individuals using an oral hypoglycemic
agent, irrespective of insulin use, in 2012. Incident
cases were individuals using an oral hypoglycemic
agent in 2012 who had not used one in the past.
Population level estimates were calculated and stratified
by age and sex.
Results: In 2012, there were 114 957 prevalent
cases of type 2 diabetes giving a population
prevalence of 2.51% (95% CI 2.49% to 2.52%).
Among adults (≥15yrs), this was 3.16% (95% CI
3.15% to 3.18%). The highest prevalence was in
those aged 70+ years (12.1%). 21 574 people
developed type 2 diabetes in 2012 giving an overall
incidence of 0.48% (95% CI 0.48% to 0.49%). In
adults, this was 0.60% (95% CI 0.60% to 0.61%).
Incidence rose with age to a maximum of 2.08%
(95% CI 2.02% to 2.15%) in people aged 65–
69 years. Men had a higher prevalence (2.96% vs
2.04%) and incidence (0.54% vs 0.41%) of type 2
diabetes than women.
Conclusions: Pharmacy claims data allow estimates
of objectively defined type 2 diabetes at the
population level using up-to-date data. These
estimates can be generated quickly to inform health
service planning or to evaluate the impact of
population level interventions.
INTRODUCTION
Diabetes mellitus is a leading cause of death
globally, causing almost 4 million deaths in
2010.1 Morbidity arising from the disease is
also substantial; the Global Burden of
Disease study estimated a 30% increase in
disability-adjusted life years for diabetes
between 1990 and 2010 due to increasing
prevalence of the disease and increased lon-
gevity of those living with diabetes.2
To reduce diabetes-related mortality and
morbidity, access to appropriate healthcare
services for people with diabetes is a neces-
sity. For this to be successful, up-to-date
population level estimates of disease burden
are required to rationally plan and deliver
the required health services.
The Institute of Public Health (IPH) esti-
mates and forecasts for the prevalence of dia-
betes (combined type 1 and type 2) are
often cited and are a valuable resource.3
However, the most recent estimates from the
IPH are based on a cross-sectional survey of
adults in the Survey of Lifestyle, Attitudes
and Nutrition (SLAN) which dates back to
2007.3 4
Other estimates of diabetes prevalence
come from The Irish Longitudinal Study of
Ageing (TILDA), which is limited to those
over 50 years,5 6 the Mitchelstown cohort
which was limited to adults aged 50–69 years
Key messages
▸ Many estimates for the burden of diabetes come
from cohort studies and surveys, which are
often not population based. There are very few
estimates of incidence of diabetes globally.
▸ We used a national administrative pharmacy
claims database to calculate prevalence and inci-
dence of type 2 diabetes. This method captures
all treated cases of diabetes and thus avoids
problems with sampling and generalizing to
whole populations that arise from cohort and
survey methods.
▸ Understanding the true burden of disease in our
society is essential for the planning of health
services, which in turn help achieve optimal out-
comes in terms of diabetes-related morbidity
and mortality. Using pharmacy claims data is a
straightforward method of achieving up to date
estimates.
BMJ Open Diabetes Research and Care 2017;5:e000288. doi:10.1136/bmjdrc-2016-000288 1
Open Access Research
in one rural area in the South of Ireland7 and the
Central Statistics Ofﬁce (CSO) Quarterly National
Household Survey (QNHS) from 2010.8 These estimates
are based on a variety of self-reported doctor diagnosis;
self-reported diabetes medication usage; or a combination
of self-report and HbA1c data; and all are limited to adult
populations. Furthermore, there is a scarcity of data avail-
able on the incidence of diabetes in Ireland.9
In this study, we used national pharmacy claims data
to estimate the prevalence and incidence of type 2 dia-
betes. These data provide an objective measure of
treated diabetes in the total population to complement
existing sample-based estimates.
METHODS
Health system
In Ireland, access to and reimbursement for diabetes
medicines occur via two publicly funded community
drug schemes. The ﬁrst is the General Medical Services
(GMS) scheme; the main public health insurance
program providing primary and secondary healthcare
free at the point of access to ∼40% of the Irish popula-
tion on a means-tested basis.10 Medicines are included
under this scheme but are subject to a copayment
(€2.50 currently). The second drug scheme is the long-
term illness (LTI) scheme. The LTI provides free access
to condition-related medicines for individuals diagnosed
with any of 16 chronic illnesses including diabetes. LTI
coverage is independent of income.
Data
Pharmacists dispensing medicines to all patients (adults
and children) on the GMS and the LTI scheme are
reimbursed by the government via the Health Service
Executive-Primary Care Reimbursement Service
(HSE-PCRS). We used dispensing data from the HSE-
PCRS database from July 2011 to December 2012. Data
were available for the drug dispensed (classiﬁed by
WHO Anatomical Therapeutic Chemical (WHO ATC)
code), date dispensed, quantity and strength, in addition
to patient age and sex.
Population denominator data for the year 2012 were
population estimates derived by the CSO based on the
2011 census.11
Definitions
Type 2 diabetes was classiﬁed as using any strength or
quantity of an oral hypoglycemic agent (WHO ATC
A10B), irrespective of age or insulin use. The different
agents included in this study, stratiﬁed by age and sex,
are given in table 1.
Calculation of incidence and prevalence
To estimate the prevalence of type 2 diabetes, we used
dispensing data for 2012. We counted the number of
people in the database who met our deﬁnition of type 2
diabetes and used this as the numerator. The total popula-
tion count published by the CSO was the denominator.11
To establish the annual incidence for type 2 diabetes
in 2012, we used data from July 2011 to December 2012.
An individual’s ﬁrst occurrence in 2012 meeting the def-
inition of type 2 diabetes was referred to as the index
date. A 6 month look-back period was used to rule out
prior use before the index date. If no prior use of an
oral hypoglycemic agent occurred in the look-back
period, then the individual was an incident user of oral
hypoglycemic medicines and thus an incident case. This
count was used as the numerator, while the denominator
was the total population count published by the CSO
minus the number of prevalent of cases.11
We carried out subgroup analyses by age group
(<15 years, ≥15 years, 15–24 years, 25–34 years, 35–
44 years, 45–54 years, 55–64 years, 65–69 years and
>70+ years) and sex.
RESULTS
In 2012, 1 655 013 people accessed a prescription on the
GMS scheme and were available in our data set. The mean
Table 1 Types of medicines used in 2012
Medicine group
Biguanides Sulfonylureas Thiazolidinediones DPP-4 Other Total
A10BA A10BB A10BG A10BH A10BC, A10BF, A10BX
n (%)WHO ATC code n (%) n (%) n (%) n (%) n (%)
Total 907 125 (51.9) 527, 886 (30.2) 25 658 (1.5) 126 345 (7.2) 60 069 (3.4) 1 747 755 (100.0)
<15 years 1547 (50.0) 914 (29.5) 50 (1.6) 142 (4.6) 139 (4.5) 3096 (0.18)
15–24 years 2959 (69.7) 675 (15.9) 57 (1.3) 178 (4.2) 212(5.0) 4247 (0.24)
25–34 years 12 537 (67.6) 3020 (16.3) 247 (1.3) 734(4.0) 1088 (5.9) 18 554 (1.06)
35–44 48 558 (59.3) 17 542 (21.4) 1243 (1.5) 4414 (5.4) 4787 (5.8) 81 960 (4.7)
45–54 years 125 732 (54.0) 57 833 (24.8) 3553 (1.5) 14 760 (6.3) 14 168 (6.1) 232 955 (13.3)
55–64 years 236 515 (52.6) 122 554 (27.3) 7493 (1.7) 31 253 (6.9) 20 675 (4.6) 449 432 (25.7)
65–69 years 140 569 (52.0) 79 897 (29.6) 4372 (1.6) 20 725 (7.7) 7936 (2.9) 270 106 (15.5)
70+ years 333 853 (49.3) 242 256 (35.8) 8435 (1.3) 53 435 (7.9) 10 600 (1.6) 677 401 (38.8)
Women 368 707 (53.2) 204 465 (29.5) 9450 (1.4) 49 794 (7.2) 25 412 (3.7) 692 565 (39.6)
Men 536 766 (51.0) 322 465 (30.7) 16 073 (1.5) 76 275 (7.3) 34 545 (3.3) 1 051 910 (60.2)
Numbers are numbers of prescriptions in 2012.
Other includes sulfonamides, α glucosidase inhibitors and ‘other’ agents as defined by WHO ATC dictionary.
DPP-4, dipeptidyl peptidase-4 inhibitors.
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age was 42.9 years (SD 25.9), and the population was
54.4% women. On the LTI scheme, 68 996 people accessed
at least one prescription in 2012. The mean age was
48.4 years (SD 25.2), and the population was 38% women.
Type 2 diabetes mellitus
In 2012, 114 957 people were classiﬁed as prevalent type
2 diabetes cases, leading to a prevalence of 2.51% (95%
CI 2.49% to 2.52%) in the total population. After
excluding those aged <15 years, an adult population
prevalence of 3.16% (95% CI 3.15% to 3.18%) was
obtained (table 2). Figure 1 demonstrates how the
prevalence increased with age; 55–64 years (6.50%),
65–69 years (10.75%) and 70+ years (12.10%). Men had
a higher prevalence of type 2 diabetes than women at
2.96% (95% CI 2.94 to 2.98) vs 2.04% (95% CI 2.02% to
2.06%) (χ2 test for homogeneity p<0.0001).
In the same year, 21 574 people developed type 2 dia-
betes giving an incidence of 0.48% (95% CI 0.48% to
0.49%). This was estimated at 0.60% (95% CI 0.60% to
0.61%) in the population aged ≥15 years. The incidence
of type 2 diabetes increased with age, reaching its highest
level of 2.08% (95% CI 2.02 to 2.15) in people aged
65–69 years. Men had a higher incidence of type 2 diabetes
(0.54%) than women (0.41%) (table 2 and ﬁgure 1).
DISCUSSION
This cross-sectional study estimated the prevalence and
incidence of type 2 diabetes using population level data
from a national pharmacy claims database. The overall
prevalence in the adult population was 3.16%. The inci-
dence of type 2 diabetes was 6 cases per 1000 adult
people in 2012.
Existing prevalence estimates pertaining to the
general adult population range from 3% in the
Quarterly National Household survey to 3.5% in those
aged ≥18 years using SLAN survey data.4 8 Our estimate
of 3.16% is thus comparable to previous ﬁgures. In add-
ition, our age stratiﬁed estimates for people aged
≥50 years are similar to those based on TILDA using
self-report of doctor diagnosis and HbA1c measures.5 6
However, our estimates may underestimate the true
burden of diabetes given that we have excluded type 1
diabetes and we also could not account for lifestyle-
treated diabetes or undiagnosed diabetes. Despite this,
the true prevalence rate of diabetes in Ireland is likely
lower than that in the USA which was recently estimated
at 8.3% in the adult population.12 In England, diag-
nosed diabetes in the population aged ≥16 years is esti-
mated at 5.6% from Health Survey for England data.13
The only other estimate of incidence of type 2 dia-
betes in Ireland is 2 cases per 1000, in contrast to the 6
cases per 1000 we found in this study.9 An American
study using the National Health Interview Survey found
an incidence rate of 7.1/1,000 people aged ≥20 years in
2012, indicating that Irish incidence rates are below
those in North America.12 A recent Danish study calcu-
lated incidence rates for every year of age.14 While it is
Table 2 Prevalence and incidence of type 2 diabetes
GMS LTI Total Population (CSO) Estimate (%) 95% CI
Prevalence estimates
Total population 81 177 33 780 114 957 4 585 000 2.51 2.49 to 2.52
Total population ≥15 years 80 618 32 987 113 605 3 590 600 3.16 3.15 to 3.18
<15 years 721 1198 1919 994 800 0.19 0.18 to 0.20
15–24 years 594 128 722 553 500 0.13 0.12 to 0.14
25–34 years 1702 765 2467 733 500 0.34 0.32 to 0.35
35–44 years 4309 3081 7390 700 000 1.06 1.03 to 1.08
45–54 years 8964 8088 17 052 586 300 2.91 2.87 to 2.95
55–64 years 16 466 13 938 30 404 468 000 6.50 6.43 to 6.57
65–69 years 12 396 7120 19 516 181 500 10.75 10.61 to 10.90
70+ years 41 098 3397 44 495 367 800 12.10 11.99 to 12.20
Women 36 968 10 231 47 199 2 315 800 2.04 2.02 to 2.06
Men 43 707 23 510 67 217 2 269 600 2.96 2.94 to 2.98
Incidence estimates
Total population 15 788 5786 21 574 4 470 043 0.48 0.48 to 0.49
Total population ≥15 years 15 353 5679 21 032 3 476 995 0.60 0.60 to 0.61
<15 years 213 234 447 992 881 0.05 0.04 to 0.05
15–24 years 405 55 460 552 678 0.08 0.08 to 0.09
25–34 years 936 293 1229 731 033 0.17 0.16 to 0.18
35–44 years 1584 819 2403 692 610 0.35 0.33 to 0.36
45–54 years 2459 1523 3982 569 248 0.70 0.68 to 0.72
55–64 years 3485 2026 5511 437 596 1.26 1.23 to 1.29
65–69 years 2406 971 3377 161 984 2.08 2.02 to 2.15
70+ years 5585 413 5998 323 305 1.86 1.81 to 1.9
Women 7242 1959 9201 2 268 601 0.41 0.40 to 0.41
Men 8165 3815 11 980 2 202 383 0.54 0.53 to 0.55
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difﬁcult to compare single age estimates with estimates
for age categories, our estimates appear comparable to
those in the Danish study, albeit somewhat higher in the
older age groups.14 Making international comparisons is
helpful to aid in understanding the plausibility of our esti-
mates, however differences do exist between populations
for demographic and methodological reasons.15
The study is limited by lack of information on undiag-
nosed diabetes and lifestyle-treated diabetes. Other data
sources, for example the Mitchelstown Cohort and
SLAN survey, provide information on undiagnosed dia-
betes, which can be used in tandem with our results.4 7
Unpublished data from the Mitchelstown Cohort study
of over 2000 adults aged 50–69 years reveal that ∼7% of
those with self-reported diabetes are treated with diet
only.16 Although these data are not nationally represen-
tative, they provide some context on the magnitude of
underestimation. Furthermore, we relied on diagnosed
individuals adhering to their treatment regimens, their
dispensed medications thus appearing in the pharmacy
claims database. We did not anticipate non-adherence to
be a major problem given that medicines are free on
the LTI scheme and subject to a small copayment on
the GMS scheme (€0.50 per item in 2012).17
The study is strengthened by the objective and reliable
nature of the data.18 Additionally, because diabetes
medicines are generally provided only through the GMS
and LTI drug schemes, data on those with diagnosed
and treated diabetes should be nationally complete
in this database offering population level data for
all ages, including children, in contrast to previous
surveys and cohort studies which are limited to adults.
Unfortunately, the database does not have access to diag-
nosis codes, thus we made the assumption that all oral
hypoglycemic agents were being used to treat diabetes.
A notable exception is the use of metformin for polycys-
tic ovarian syndrome (PCOS). However, as PCOS effects
only a small proportion of women of reproductive age,
∼8%, and only some of these will be treated, any effect
on our estimates is likely to be small. Further, many
women with PCOS will have diabetes, and we will have
intended to include them in our estimates.19 Metformin
is also used in pre-diabetes, which due to lack of diagno-
sis codes, we have not been able to separate from our
estimates. We know from our prior research that the
prevalence of pre-diabetes in those aged ≥45 years is
20%.20 From the most recent audit of diabetes manage-
ment in General Practice, we know that ∼90% of those
with pre-diabetes are treated with dietary intervention
(unpublished).21 Thus, any bias contributed to our
results from including those with metformin-treated pre-
diabetes is likely to be inconsequential.
Our study has demonstrated the utility of routinely
collected administrative claims data in calculating mea-
sures of disease burden, including incidence. The
method is straightforward, and while we used data from
2012 for this study, more current data would allow esti-
mating disease burden for the most recently completed
calendar year along with establishing longitudinal
trends. This approach affords advantages in real-time
monitoring of disease burden and thus presents a key
resource for evaluating public health interventions to
reduce the prevalence and incidence of type 2 diabetes,
thus informing health policy and health service plan-
ning. To address acknowledged weaknesses in using
these data, estimates for prevalence and incidence
should be considered in combination with cross-
sectional and cohort study results to account for undiag-
nosed and lifestyle-treated cases.
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